Coherus Oncology (CHRS) vs ImageneBio (IMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImageneBio (IMA) has outperformed Coherus Oncology (CHRS) over the past year, losing 44.9% versus a loss of 68.1%. Over five years, IMA leads with a -97.9% price change compared with -98.0% for CHRS. Coherus Oncology is the larger company by market cap ($57.1 million vs $48.8 million), about 1.2 times the size.
Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus -5668.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | IMA |
|---|---|---|
| Share price | $0.3698 | $3.92 |
| Market cap | $57.15M | $48.83M |
| 1-day change | -4.47% | 0.00% |
| YTD return | -73.96% | -43.19% |
| 1-year return | -68.12% | -44.87% |
| 5-year return | -97.99% | -97.86% |
| EPS (TTM) | $-1.12 | $-2.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $42.17M | $800.00K |
| Revenue growth (YoY) | +59.81% | -77.14% |
| Net income (latest FY) | $168.02M | $-45.35M |
| Gross margin | 67.24% | — |
| Operating margin | -429.51% | -6056.38% |
| Net margin | 398.43% | -5668.63% |
| 52-week high | $2.62 | $7.60 |
| 52-week low | $0.3628 | $3.00 |
| Distance from 52-week high | -85.86% | -48.42% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1995.73% | +359.18% |
| Average volume | 1.80M | 15.86K |
| Shares outstanding | 154.54M | 12.46M |
| Employees | 144 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMA has outperformed CHRS by 23.3 percentage points over the past year.
- Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus -5668.6 cents for ImageneBio.
- Coherus Oncology grew revenue faster in its latest fiscal year (+59.81% vs -77.14%).
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
About ImageneBio
IMA stock →ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
CHRS vs IMA FAQ
Which is bigger, Coherus Oncology or ImageneBio?
Coherus Oncology (CHRS) is larger, with a market capitalization of $57.15M compared with $48.83M for ImageneBio (IMA).
Which stock has performed better over the past year, CHRS or IMA?
IMA returned -44.87% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and ImageneBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.